Skip to main content
. 2017 Apr 7;8(30):49033–49043. doi: 10.18632/oncotarget.16931

Figure 3. Images and quantification of EdU staining following 48-h treatment with cisplatin and cisplatin plus WP1130.

Figure 3

Compared with cisplatin alone, WP1130 and cisplatin co-treatment reduced the proliferative ability of A549 cells (A) and HCC827 cells (B) in an obvious manner, but not that of NCI-H1299 cells (C). **P < 0.01. (D) Apoptotic NSCLC cells were determined with flow cytometry following treatment with cisplatin alone or cisplatin combined with WP1130. WP1130 and cisplatin co-treatment increased the apoptosis rate of NCI-H1299 cells, but not that of A549 and HCC827 cells. *P < 0.05 vs. cisplatin.